Recently public Envision Healthcare (EVHC) gets a bevy of new coverage.
Goldman starts the shares at Neutral (price target $26) noting that the although the company "has demonstrated the ability to grow both organically and through industry roll-up ... much of the upside from its multiple growth drivers [is] currently priced into its stock."
Deutsche initiates at Buy (price target $31) citing EVHC's market leading position in "hospital-based physician outsourcing and medical transportation [as well as its status] as an innovator in the post-acute care management space."
Cantor starts the shares at Buy, saying EVHC's "businesses are highly complementary" and noting that "the company will continue to grow as the population ages, cost pressures increase the percentage of these businesses that are outsourced, and the industry consolidates."
EVHC +2% premarket